Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Wellness
Home & Realty
Outdoor Guide
Women
Class of 2023
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innoviva Inc
(NQ:
INVA
)
12.93
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 21, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
12.93
Bid (Size)
11.77 (1)
Ask (Size)
13.76 (5)
Prev. Close
12.93
Today's Range
12.93 - 12.93
52wk Range
10.64 - 13.90
Shares Outstanding
65,504,384
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Innoviva to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Innoviva, Inc.
Via
Business Wire
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
September 18, 2023
From
Innoviva, Inc.
Via
Business Wire
Performance
YTD
-2.56%
-2.56%
1 Month
-2.42%
-2.42%
3 Month
+0.23%
+0.23%
6 Month
+15.55%
+15.55%
1 Year
+7.48%
+7.48%
More News
Read More
Innoviva Appoints Stephen Basso as Chief Financial Officer
August 25, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 02, 2023
From
Innoviva, Inc.
Via
Business Wire
A Look Into Healthcare Sector Value Stocks
May 15, 2023
Via
Benzinga
5 Value Stocks In The Healthcare Sector
May 08, 2023
Via
Benzinga
Overview Of Value Stocks In The Healthcare Sector
July 31, 2023
Via
Benzinga
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
July 11, 2023
Via
InvestorPlace
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
June 06, 2023
From
Innoviva, Inc.
Via
Business Wire
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
May 24, 2023
Via
Benzinga
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 23, 2023
From
Innoviva, Inc.
Via
Business Wire
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
April 18, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Innoviva
March 03, 2023
Via
Benzinga
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
May 16, 2023
Via
Benzinga
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
May 11, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Earnings Perspective: Return On Capital Employed
December 19, 2022
Via
Benzinga
Innoviva Announces Retirement of Board Chairman
April 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
April 18, 2023
Via
Benzinga
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Stock Trading Halted Today
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
March 13, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
February 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Four Undervalued Healthcare Stocks for 2023
January 06, 2023
Via
MarketBeat
Exposures
COVID-19
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
November 30, 2022
From
Innoviva, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.